Clinical trials: Epistaxis Nosebleed
Epistaxis
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
Between 10 and 12% of the general population suffers from epistaxis, out of which 10% would need to be medically managed. Most of patients treated for epistaxis are managed through emergency departments.
- Trial name
- BATSI (NCT03912051)
- Testing
- asymmetric balloon
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Dianosic
Hereditary Hemorrhagic Telangiectasia (HHT)
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
- Trial name
- NCT07255846
- Testing
- TER-1754
- Where
- United States
- Sponsor
- Terremoto Biosciences Inc.
Epistaxis
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
Purpose: This study is a prospective clinical trial to investigate the efficacy of a chitosan-coated nasal packing (ChitoFlex® used in conjunction with the HemCon Nasal Plug) in the management of difficult spontaneous epistaxis…
- Trial name
- NCT00863356
- Testing
- 2009-I-Epistaxis-1
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HemCon Medical Technologies, Inc
Epistaxis Nosebleed
Nasal Compression Device Study for Epistaxis
This study will explore how a nasal compression device compares to manual compression for stopping anterior nosebleeds. This will be a non-randomized controlled trial enrolling participants presenting to medical care for anterior…
- Trial name
- NCT05789264
- Testing
- Nasal Compression Device, Routine Care
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NasaClip
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Dry Nose, Nose Irritation
Pilot Study to Assess Performance and Safety of SULFEX 13081.22 Nasal Spray in Patients With Dry or Irritated Nose
As the medical device is CE marked, the objective of this study is to provide performance and safety data on SULFEX 13081.22 nasal spray as close as possible to the routine care.
- Trial name
- NCT05499078
- Testing
- SULFEX 13081.22
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Church & Dwight Company, Inc.